Diagnostic imaging services provider RadNet will acquire iCAD in an all stock transaction where iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting with Guardant Health (NASDAQ:GH).
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare providers & services industry, including AMN Healthcare Services (NYSE:AMN) and its peers.
Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers.
RadNet has gotten torched over the last six months - since September 2024, its stock price has dropped 25.7% to $51.34 per share. This may have investors wondering how to approach the situation.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting with RadNet (NASDAQ:RDNT).
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst performers in the testing & diagnostics services industry.
Diagnostic imaging company RadNet (NASDAQ:RDNT) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 13.5% year on year to $477.1 million. On the other hand, the company’s full-year revenue guidance of $1.94 billion at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.07 per share was 40.7% below analysts’ consensus estimates.
